普瑞巴林用于原发性脑肿瘤伴癫痫患者：一项初步观察
Pregabalin in patients with primary brain tumors and seizures: a preliminary observation.
作者信息
Novy Jan, Stupp Roger, Rossetti Andrea O
机构信息
Department of Neurology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
出版信息
Clin Neurol Neurosurg. 2009 Feb;111(2):171-3. doi: 10.1016/j.clineuro.2008.09.009. Epub 2008 Nov 1.
OBJECTIVES
Patients with brain tumors and seizures should be treated with non-enzyme-inducing antiepileptic drugs (AED). Some of the newer drugs seem particularly suited in these patients.
METHODS
Here we describe our experience with pregabalin (PGB); its effectiveness was retrospectively studied in nine consecutive patients with primary brain tumors and seizures.
RESULTS
Six subjects had secondarily generalized and three simple partial seizures. Patients mostly suffered from WHO grade IV gliomas. PGB replaced enzyme inducing, inefficacious or bad tolerated AED, as add-on or monotherapy. Median follow-up was 5 (2-19) months; three patients died of their tumor. Daily median dosage was 300 mg. All subjects experienced at least a 50% seizure reduction, six were seizure-free. Side effects were reported in four patients, leading to PGB discontinuation in two.
CONCLUSION
PGB appears to have a promising effectiveness in this setting, even as a monotherapy. Based on these results we embarked on a prospective controlled trial.
目的
脑肿瘤伴癫痫发作的患者应使用非酶诱导性抗癫痫药物（AED）进行治疗。一些新型药物似乎特别适合这些患者。
方法
在此，我们描述了我们使用普瑞巴林（PGB）的经验；对连续9例原发性脑肿瘤伴癫痫发作的患者进行了回顾性研究，以评估其有效性。
结果
6例患者出现继发性全身性发作，3例为单纯部分性发作。患者大多患有世界卫生组织IV级胶质瘤。PGB替代了酶诱导性、无效或耐受性差的AED，作为附加治疗或单一疗法。中位随访时间为5（2 - 19）个月；3例患者死于肿瘤。每日中位剂量为300 mg。所有患者的癫痫发作至少减少了50%，6例患者无癫痫发作。4例患者报告有副作用，其中2例因此停用PGB。
结论
在这种情况下，PGB似乎具有良好的疗效，即使作为单一疗法也是如此。基于这些结果，我们开展了一项前瞻性对照试验。
Zotero 插件